Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Biomed 101 may protect normal cells from the side effects of interleukin-2.
PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients receiving interleukin-2 for kidney cancer.
100 项与 Biomed-101 相关的临床结果
100 项与 Biomed-101 相关的转化医学
100 项与 Biomed-101 相关的专利(医药)
100 项与 Biomed-101 相关的药物交易